Immunoglobulin treatment for myasthenia gravis with thymoma
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study compares two treatments for myasthenia gravis (a nerve-muscle condition causing weakness) that occurs with a thymoma (a tumor in the thymus). You will receive one of two medicines before surgery to remove the thymoma, to see which better improves muscle strength and daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and expected to live more than a year.
- You have generalized myasthenia gravis, meaning it affects more than just your eyes, and you have a positive AChR antibody test.
- Your symptoms are noticeable and affect daily activities, like drooping eyelids, double vision, or weakness in arms or legs.
- You have been diagnosed with a thymoma (a tumor in the thymus) and your doctor plans to remove it with surgery.
- You are in relatively good health (classified as ASA 1-2) and do not have severe heart, lung, kidney, or liver problems, or active infections or bleeding disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the thymus gland and certain antibodies relate to myasthenia gravis, a condition that causes muscle weakness. It may help doctors understand the disease better and could lead to improved treatments.
This early study tests a new cell therapy (GC012F) for people with difficult-to-treat generalized myasthenia gravis. The treatment aims to reset the immune system to reduce muscle weakness.
This trial tests the drug efgartigimod given before and after surgery for people with myasthenia gravis and a thymoma. The goal is to see if it helps improve symptoms and recovery around the operation.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This study tests a new combination treatment for generalized myasthenia gravis. It combines two medications to help reduce muscle weakness and improve your daily life.
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
Hear when a new Myasthenia Gravis Associated With Thymoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.